EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Integration of peripheral blood‐ and tissue‐based biomarkers of response to immune checkpoint blockade in urothelial carcinoma

Rami S Vanguri iD, James W Smithy iD, Yanyun Li, Mingqiang Zhuang, Colleen A Maher, Nathaniel Aleynick, Xiyu Peng, Hikmat Al-Ahmadie iD, Samuel A Funt, Jonathan E Rosenberg, Gopa Iyer, Dean Bajorin and 6 more

The Journal of Pathology · 2023-11 · 261 (3) · 349-360

DOI: 10.1002/path.6197 ↗

At a glance

Journal article in The Journal of Pathology, published online on 2023-09-05. Written by Rami S Vanguri and 17 co-authors. Institution: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Major MEDLINE topics: Immune Checkpoint Inhibitors, Biomarkers, Tumor. Cited 15 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NCI NIH HHS, National Cancer Institute.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

As predictive biomarkers of response to immune checkpoint inhibitors (ICIs) remain a major unmet clinical need in patients with urothelial carcinoma (UC), we sought to identify tissue‐based immune biomarkers of clinical benefit to ICIs using multiplex immunofluorescence and to integrate these findings with previously identified peripheral blood biomarkers of response. Fifty‐five pretreatment and 12 paired on‐treatment UC specimens were identified from patients treated with nivolumab with or without ipilimumab. Whole tissue sections were stained with a 12‐plex mIF panel, including CD8, PD‐1/CD279, PD‐L1/CD274, CD68, CD3, CD4, FoxP3, TCF1/7, Ki67, LAG‐3, MHC‐II/HLA‐DR, and pancytokeratin+SOX10 to identify over three million cells. Immune tissue densities were compared to progression‐free survival (PFS) and best overall response (BOR) by RECIST version 1.1. Correlation coefficients were calculated between tissue‐based and circulating immune populations. The frequency of intratumoral CD3 + LAG‐3 + cells was higher in responders compared to nonresponders ( p = 0.0001). LAG‐3 + cellular aggregates were associated with response, including CD3 + LAG‐3 + in proximity to CD3 + ( p = 0.01). Exploratory multivariate modeling showed an association between intratumoral CD3 + LAG‐3 + cells and improved PFS independent of prognostic clinical factors (log HR −7.0; 95% confidence interval [CI] −12.7 to −1.4), as well as established biomarkers predictive of ICI response (log HR −5.0; 95% CI −9.8 to −0.2). Intratumoral LAG‐3 + immune cell populations warrant further study as a predictive biomarker of clinical benefit to ICIs. Differences in LAG‐3 + lymphocyte populations across the intratumoral and peripheral compartments may provide complementary information that could inform the future development of multimodal composite biomarkers of ICI response. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Immune Checkpoint InhibitorsBiomarkers, TumorHumansMaleFemaleAgedMiddle AgedUrinary Bladder NeoplasmsProgression-Free SurvivalAged, 80 and overCarcinoma, Transitional CellLymphocytes, Tumor-InfiltratingNivolumabUrologic NeoplasmsIpilimumabTreatment Outcome

Author keywords

LAG-3biomarkerscheckpoint blockadeflow cytometryimmunotherapymultimodal integrationmultiplex immunofluorescenceurothelial carcinoma

Substances

Immune Checkpoint InhibitorsBiomarkers, TumorNivolumabIpilimumab

Authors and institutions

  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Medicine, Weill Cornell Medical College, New York, NY, USA.

ORCID profiles: Rami S Vanguri, James W Smithy, Hikmat Al-Ahmadie

Funding

  • NCI NIH HHS
  • National Cancer Institute

Cite

APA

Vanguri, R. S., Smithy, J. W., Li, Y., Zhuang, M., Maher, C. A., Aleynick, N., Peng, X., Al-Ahmadie, H., Funt, S. A., Rosenberg, J. E., Iyer, G., Bajorin, D., Mathews, J. C., Nadeem, S., Panageas, K. S., Shen, R., Callahan, M. K., & Hollmann, T. J. (2023). Integration of peripheral blood‐ and tissue‐based biomarkers of response to immune checkpoint blockade in urothelial carcinoma. The Journal of Pathology, 261(3), 349-360. https://doi.org/10.1002/path.6197

Vancouver

Vanguri RS, Smithy JW, Li Y, Zhuang M, Maher CA, Aleynick N, et al. Integration of peripheral blood‐ and tissue‐based biomarkers of response to immune checkpoint blockade in urothelial carcinoma. The Journal of Pathology. 2023;261(3):349-360. doi:10.1002/path.6197

BibTeX
@article{Vanguri2023,
  author = {Vanguri, Rami S and Smithy, James W and Li, Yanyun and Zhuang, Mingqiang and Maher, Colleen A and Aleynick, Nathaniel and Peng, Xiyu and Al-Ahmadie, Hikmat and Funt, Samuel A and Rosenberg, Jonathan E and Iyer, Gopa and Bajorin, Dean and Mathews, James C and Nadeem, Saad and Panageas, Katherine S and Shen, Ronglai and Callahan, Margaret K and Hollmann, Travis J},
  title = {Integration of peripheral blood‐ and tissue‐based biomarkers of response to immune checkpoint blockade in urothelial carcinoma},
  journal = {The Journal of Pathology},
  year = {2023},
  volume = {261},
  number = {3},
  pages = {349--360},
  doi = {10.1002/path.6197}
}
Start for free →